BR112022017508A2 - Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos - Google Patents
Inibidores de egfr, kras, braf e outros alvos e uso dos mesmosInfo
- Publication number
- BR112022017508A2 BR112022017508A2 BR112022017508A BR112022017508A BR112022017508A2 BR 112022017508 A2 BR112022017508 A2 BR 112022017508A2 BR 112022017508 A BR112022017508 A BR 112022017508A BR 112022017508 A BR112022017508 A BR 112022017508A BR 112022017508 A2 BR112022017508 A2 BR 112022017508A2
- Authority
- BR
- Brazil
- Prior art keywords
- braf
- kras
- egfr
- target inhibitors
- inhibitors
- Prior art date
Links
- 102100030708 GTPase KRas Human genes 0.000 title abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 title abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INIBIDORES DE EGFR, KRAS, BRAF E OUTROS ALVOS E USO DOS MESMOS. São fornecidos no presente documento compostos que são úteis no tratamento de câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985549P | 2020-03-05 | 2020-03-05 | |
| PCT/US2021/020987 WO2021178740A1 (en) | 2020-03-05 | 2021-03-05 | Inhibitors of egfr, kras, braf, and other targets and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017508A2 true BR112022017508A2 (pt) | 2022-11-16 |
Family
ID=77612747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017508A BR112022017508A2 (pt) | 2020-03-05 | 2021-03-05 | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230097789A1 (pt) |
| EP (1) | EP4114387A4 (pt) |
| JP (1) | JP2023515691A (pt) |
| KR (1) | KR20220150917A (pt) |
| CN (1) | CN115397413A (pt) |
| AU (1) | AU2021230372A1 (pt) |
| BR (1) | BR112022017508A2 (pt) |
| CA (1) | CA3172812A1 (pt) |
| IL (1) | IL296034A (pt) |
| MX (1) | MX2022010975A (pt) |
| WO (1) | WO2021178740A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113164418A (zh) | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547977A (en) * | 1967-10-27 | 1970-12-15 | Velsicol Chemical Corp | Novel carbanilates |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| CA3091834A1 (en) * | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
-
2021
- 2021-03-05 CA CA3172812A patent/CA3172812A1/en active Pending
- 2021-03-05 WO PCT/US2021/020987 patent/WO2021178740A1/en not_active Ceased
- 2021-03-05 IL IL296034A patent/IL296034A/en unknown
- 2021-03-05 JP JP2022552646A patent/JP2023515691A/ja active Pending
- 2021-03-05 AU AU2021230372A patent/AU2021230372A1/en not_active Abandoned
- 2021-03-05 EP EP21763625.7A patent/EP4114387A4/en not_active Withdrawn
- 2021-03-05 US US17/801,327 patent/US20230097789A1/en not_active Abandoned
- 2021-03-05 KR KR1020227033358A patent/KR20220150917A/ko not_active Withdrawn
- 2021-03-05 CN CN202180025271.0A patent/CN115397413A/zh active Pending
- 2021-03-05 BR BR112022017508A patent/BR112022017508A2/pt not_active Application Discontinuation
- 2021-03-05 MX MX2022010975A patent/MX2022010975A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021178740A1 (en) | 2021-09-10 |
| CN115397413A (zh) | 2022-11-25 |
| EP4114387A1 (en) | 2023-01-11 |
| JP2023515691A (ja) | 2023-04-13 |
| CA3172812A1 (en) | 2021-09-10 |
| KR20220150917A (ko) | 2022-11-11 |
| US20230097789A1 (en) | 2023-03-30 |
| MX2022010975A (es) | 2022-12-02 |
| AU2021230372A1 (en) | 2022-09-22 |
| IL296034A (en) | 2022-10-01 |
| EP4114387A4 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017508A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| BR112022017724A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| JOP20240136A1 (ar) | تركيب صيدلاني يشتمل على مركب كينازولين | |
| BR112021022504A2 (pt) | Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos | |
| BR112021022576A2 (pt) | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos | |
| CY1123577T1 (el) | Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2 | |
| CA3155857A1 (en) | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| EP4600247A3 (en) | Pd-1/pd-l1 inhibitors | |
| BR112023009531A2 (pt) | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| BR112021025544A2 (pt) | Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos | |
| CY1125158T1 (el) | Συνθεσεις για την αγωγη καρκινου με εξαντληση αργινινης και ανοσο-ογκολογικους παραγοντες | |
| IL285316A (en) | Detecting cancer, cancer tissue of origin, and/or a cancer cell type | |
| MY209360A (en) | Anti-cd47 and anti-cd20 based treatment of blood cancer | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| WO2021247794A3 (en) | B7h3-targeting proteins and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |